Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 723-728

  Mahe, Julien ^a   Meurette, Aurélie ^a   Moreau, Anne ^a   Vercel, Caroline ^a   Jolliet, Pascale ^a,b  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b Universite de Nantes   (France)

Author keywords

Antiangiogenic activity; Hemolytic uremic syndrome; Interferon beta; Thrombotic microangiopathy

Indexed keywords

AMLODIPINE; BETA1A INTERFERON; FUROSEMIDE; IBUPROFEN; IRBESARTAN; NICARDIPINE; PARACETAMOL; PROPRANOLOL; URAPIDIL; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INTRAVASCULAR HEMOLYSIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; RENAL THROMBOTIC MICROANGIOPATHY; TREATMENT DURATION; CHEMICALLY INDUCED; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; INTERFERON-BETA; KIDNEY DISEASES; MULTIPLE SCLEROSIS; THROMBOTIC MICROANGIOPATHIES;

EID: 84881291352     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S42138     Document Type: Article

References (28)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687.
2. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998;53(4):836-844.
3. Medina PJ, Sipols JM, George JN. Drug associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8(5):286-293.
4. George JN, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B. Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med. 2012;41(3 Pt 2):e177-e188.
5. Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C; for Groupe D'étude Des Nephrologues D'ile-de-France (GENIF). Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine (Baltimore). 2002;81(4):321-331.
6. Aravindan A, Yong J, Killingsworth M, Suranyi M, Wong J. Minimal change disease with interferon-beta therapy for relapsing remitting multiple sclerosis. NDT Plus. 2010;3(2):132-134.
7. Harvey M, Rosenfeld D, Davies D, Hall BM. Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence? Am J Hematol. 1994;46(2):152-153.
8. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411-417.
9. Zhang B, Xing C, Yu X, Sun B, Zhao X, Qian J. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res. 2008;31(3):479-483.
10. Halevy D, Radhakrishnan J, Markowitz G, Appel G. Thrombotic microangiopathies. Crit Care Clin. 2002;18(2):309-320.
11. Piette JC, Papo T. Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant. 1995;10(9):1781.
12. IJdo JW, Conti-Kelly AM, Greco P, et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 1999;8(2):109-115.
13. Malina M, Roumenina LT, Seeman T, et al. Genetics of hemolytic uremic syndromes. Presse Med. 2012;41(3 Pt 2):e105-e114.
14. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998; 53(4):836-844.
15. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2003;100(22):12966-12971.
16. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004;41(6):e84.
17. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347(8):589-600.
18. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581-611.
19. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses. Cancer Res. 1987;47(19):5155-5161.
20. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296(5573):1653-1655.
21. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-2017.
22. ema. europa. eu [homepage on the Internet]. Summary of product characteristics of Rebif® [updated 2013 April 18] Available from: http://www.ema.europa.eu/ema/. Accessed June 26, 2013.
23. Hansen T, New D, Reeve R, Donne R, Stephens W. Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: case report and review of the literature. NDT Plus. 2009;2(6):466-468.
24. Crispin JC, Diaz-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus. 2005;14(6):495-496.
25. Ubara Y, Hara S, Takedatu H, et al. Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron. 1998;80(1):107-108.
26. Herrera WG, Balizet LB, Harberts SW, et al. Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis [American Academy of Neurology 51st annual meeting. Toronto, Ontario, Canada. April 17-24, 1999. Abstracts] Neurology 1999;52(6 Suppl. 2):A135.
27. Broughton A, Cosyns JP, Jadoul M. Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report. Clin Nephrol. 2011;76(5):396-400.
28. Olea T, Díaz-Mancebo R, Picazo ML, Martínez-Ara J, Robles A, Selgas R. Thrombotic microangiopathy associated with use of interferon-beta. Int J Nephrol Renovasc Dis. 2012;5:97-100.